- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-EIF4E-S209 Antibody Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP3474a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-EIF4E-S209 Antibody Blocking Peptide - Product info | |
| Primary Accession | P06730 |
| Clone Names | 110287 |
| Calculated MW | 25097 Da |
Phospho-EIF4E-S209 Antibody Blocking Peptide - Additional info | |
| Gene ID 1977 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP3474a was selected from the region of human Phospho-EIF4E-S209. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Phospho-EIF4E-S209 Antibody Blocking Peptide - Protein Information | |
| Name EIF4E | |
| Synonyms EIF4EL1, EIF4F | |
| Function Its translation stimulation activity is repressed by binding to the complex CYFIP1-FMR1 (By similarity). Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap | |
| Cellular Location Cytoplasm, P-body. | |
Phospho-EIF4E-S209 Antibody Blocking Peptide - Related products
AM1852a: EIF4E Antibody (Ascites)
AP1954a: EIF4E Antibody (N-term)
AP3474a: Phospho-EIF4E-S209 Antibody
RI11731: EIF4E predesign siRNA
BP3474a: Phospho-EIF4E-S209 Antibody Blocking Peptide
AJ1255b: eIF-4E Antibody (C-term)
AJ1255c: eIF-4E Antibody Phospho (pS209)
Phospho-EIF4E-S209 Antibody Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. EIF4E is also known to interact with other partners. The interaction with EIF4ENIF1 mediates the import into the nucleus. Nonphosphorylated EIF4EBP1, EIF4EBP2 and EIF4EBP3 compete with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. Rapamycin can attenuate insulin stimulation, mediated by FKBPs.
REFERENCES
Rychlik,W., J. Biol. Chem. 262 (22), 10434-10437 (1987)Dorfman,J., Genomics 9 (4), 785-788 (1991)Pelletier,J., Genomics 10 (4), 1079-1082 (1991)Whalen,S.G., J. Biol. Chem. 271 (20), 11831-11837 (1996)
